AI + Embodied Intelligence for Global Wellness

On September 20, 2019, Shenzhen DeYi Medical Technology Co., Ltd. was officially established in Shenzhen, with Chairman Zhang Chunguang. The core team consists of members from universities such as the University of Science and Technology of China, Beihang University, and the University of Beijing. The company focuses on the AI medical embodied intelligent robotics track, establishing a research and development framework of “perception, decision-making, execution, and feedback.” It initiated breakthroughs in foundational algorithms like 3D human visual recognition and intelligent acupoint identification, leveraging the Shenzhen Greater Bay Area supply chain for hardware development.

1. Continuously refine the core technologies of robotic force control, human body 3D modeling, and acupoint matching, completing the development of the first-generation AI physical therapy robot prototype.

2. Gradually build a product matrix, launch robotic series for massage and moxibustion, initiate pilot projects in traditional Chinese medicine hospitals and rehabilitation institutions, complete clinical scenario validation, accumulate collaborations with top-tier hospitals, and simultaneously secure patents while progressively accumulating invention patents and software copyrights.

1. Completed multi-generation product iterations, enriched the robot product line, and expanded into physical therapy categories such as massage, moxibustion, and shock wave therapy.

2. Rapid domestic market expansion, with equipment deployed in over a hundred cities across the country; simultaneous overseas market initiatives, achieving international certifications such as EU CE, and products sold in multiple countries, accelerating the commercialization of the “DeYi Robotics” brand.

1. Recognized as a national high-tech enterprise, with a patent pool expanded to include over 60 invention patents and 50 software copyrights. The self-developed Deep PT deep therapy model has established a comprehensive technical moat.

2. In December 2024, the company completed a Series A financing round of tens of millions of yuan, with funds allocated for product iteration, clinical validation, market expansion, and further refinement of self-developed hardware modules such as collaborative robotic arms and force control algorithms.

1. Recognized as a National-Level Science and Technology SME and a Specialized, Sophisticated, and Innovative SME in Guangdong Province, the company’s technical capabilities have been officially certified.

The product matrix has been expanded to include 10 AI physiotherapy robots, covering multiple scenarios such as hospital rehabilitation departments, traditional Chinese medicine clinics, wellness institutions, postpartum care, and elderly care. Domestically, the coverage extends to over 170 cities, with overseas expansion reaching 17 countries. The company continues to advance the registration and certification process for medical devices.